709 related articles for article (PubMed ID: 21351087)
1. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
2. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
3. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
[TBL] [Abstract][Full Text] [Related]
5. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
6. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
10. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
11. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
12. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
13. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
14. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Agarwal S; Sane R; Gallardo JL; Ohlfest JR; Elmquist WF
J Pharmacol Exp Ther; 2010 Jul; 334(1):147-55. PubMed ID: 20421331
[TBL] [Abstract][Full Text] [Related]
15. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
16. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
[TBL] [Abstract][Full Text] [Related]
17. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.
Bihorel S; Camenisch G; Lemaire M; Scherrmann JM
J Neurochem; 2007 Sep; 102(6):1749-1757. PubMed ID: 17696988
[TBL] [Abstract][Full Text] [Related]
18. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
20. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O
J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
